ATE425460T1 - Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs - Google Patents

Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs

Info

Publication number
ATE425460T1
ATE425460T1 AT01972118T AT01972118T ATE425460T1 AT E425460 T1 ATE425460 T1 AT E425460T1 AT 01972118 T AT01972118 T AT 01972118T AT 01972118 T AT01972118 T AT 01972118T AT E425460 T1 ATE425460 T1 AT E425460T1
Authority
AT
Austria
Prior art keywords
pca
patients
psa
antibody
chain
Prior art date
Application number
AT01972118T
Other languages
English (en)
Inventor
Kim Pettersson
Hans Lilja
Timo Loevgren
Pauliina Niemelae
Original Assignee
Arctic Partners Oy Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arctic Partners Oy Ab filed Critical Arctic Partners Oy Ab
Application granted granted Critical
Publication of ATE425460T1 publication Critical patent/ATE425460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01972118T 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs ATE425460T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20002127A FI20002127A0 (fi) 2000-09-27 2000-09-27 Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi

Publications (1)

Publication Number Publication Date
ATE425460T1 true ATE425460T1 (de) 2009-03-15

Family

ID=8559172

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972118T ATE425460T1 (de) 2000-09-27 2001-09-26 Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs

Country Status (9)

Country Link
US (1) US7872104B2 (de)
EP (1) EP1320756B1 (de)
JP (1) JP5254517B2 (de)
AT (1) ATE425460T1 (de)
AU (1) AU2001291911A1 (de)
DE (1) DE60137949D1 (de)
ES (1) ES2322432T3 (de)
FI (1) FI20002127A0 (de)
WO (1) WO2002027323A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
CA2853705C (en) * 2011-10-25 2021-10-12 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
EP2771037B1 (de) 2011-10-28 2016-08-03 Fredax AB Therapeutische wirkstoffe und ihre verwendung
BR112014021776B1 (pt) * 2012-03-05 2022-08-09 Opko Diagnostics, Llc Sistema de ensaio e método para a determinação de uma probabilidade de um evento associado com o câncer da próstata
JP6312141B2 (ja) * 2012-03-30 2018-04-18 国立大学法人京都大学 前立腺がん検査用尿中バイオマーカー
KR102442738B1 (ko) 2013-11-19 2022-09-15 프레닥스 에이비 인간화된 안티 칼리크레인-2 항체
SG10201808585TA (en) * 2014-03-28 2018-11-29 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
EP3922265A1 (de) * 2015-10-05 2021-12-15 Fredax AB Humanisierte anti psa (5a10) antikörper
CN109991405B (zh) * 2017-12-29 2023-01-24 上海索昕生物科技有限公司 一种免疫检测试剂盒及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635575A1 (de) * 1993-07-22 1995-01-25 Wallac Oy Monoklonale Antikörper gegen Epitope in freiem uber nicht in Alpha-1-antichymotrypsin komplexiertem Prostata spezifisches Antigen
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
JPH10150999A (ja) * 1996-11-22 1998-06-09 Eiken Chem Co Ltd ヒト前立腺特異抗原−α１−アンチキモトリプシン複合体に対するモノクローナル抗体及びそれを用いたヒト前立腺特異抗原−α１−アンチキモトリプシン複合体の免疫学的検出法
US5858685A (en) * 1997-03-21 1999-01-12 The Board Of Trustees Of The Leland Stanford Junior University Prostate specific antigen from benign prostatic hyperplasia and its use in diagnosis
US7659073B2 (en) * 1997-04-30 2010-02-09 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
CA2286090C (en) * 1997-04-30 2013-01-08 Hybritech Incorporated Forms of prostate specific antigen and methods for their detection
US7211397B2 (en) * 1999-04-30 2007-05-01 Beckman Coulter, Inc. Method of analyzing non-complexed forms of prostate specific antigen in a sample to improve prostate cancer detection
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone

Also Published As

Publication number Publication date
US7872104B2 (en) 2011-01-18
WO2002027323A1 (en) 2002-04-04
US20040101914A1 (en) 2004-05-27
DE60137949D1 (de) 2009-04-23
AU2001291911A1 (en) 2002-04-08
EP1320756B1 (de) 2009-03-11
EP1320756A1 (de) 2003-06-25
JP5254517B2 (ja) 2013-08-07
ES2322432T3 (es) 2009-06-22
FI20002127A0 (fi) 2000-09-27
JP2004509934A (ja) 2004-04-02

Similar Documents

Publication Publication Date Title
Mönig et al. Expression of MMP‐2 is associated with progression and lymph node metastasis of gastric carcinoma
Xing et al. Neuroendocrine cells in human prostate over‐express the anti‐apoptosis protein survivin
Fritzsche et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer
Chan et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen
Fritzsche et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
ATE425460T1 (de) Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
ATE524196T1 (de) An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DE69940436D1 (de) Prostata stammzellantigen (psca) und dessen verwendungen
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
WO2003024191A3 (en) Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
Zargaran et al. Immunohistochemical evaluation of type IV collagen and laminin‐332 γ2 chain expression in well‐differentiated oral squamous cell carcinoma and oral verrucous carcinoma: a new recommended cut‐off
ATE412756T1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
Moul et al. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen
ATE491727T1 (de) Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
Peltola et al. Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades
ATE404676T1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
ES2191173T3 (es) Anticuerpos monoclonales contra un complejo de act humana y una proteasa de serina.
Lilja et al. Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer
WO2002063048A3 (en) Methods for predicting sensitivity of tumors to arginine deprivation
DE60030696D1 (de) Spezifische antikörper für cyp1b1
DE60232069D1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties